LLY · News · 20261107N

Distribution Channels - Hims & Hers

ELI LILLY & Co · 2026-11-07 · Importance 34 · Surprise 42 · In source text

Eli Lilly agreed with Hims & Hers to offer its FDA-approved obesity drugs Zepbound and Foundayo through the telehealth platform. Eligible patients can access Lilly's self-pay prices, complete consultations, receive prescriptions, and arrange home delivery without leaving Hims & Hers’ service. The arrangement moves Hims & Hers’ weight-loss offering to branded GLP-1 therapies and removes compounded copies from its model, extending Lilly’s digital access and fulfillment channels.

Key facts

• Eli Lilly and Company announced an agreement with Hims & Hers Health to offer FDA-approved obesity drugs Zepbound and Foundayo on the Hims & Hers platform. source
• Under its agreement with Hims & Hers Health, Eli Lilly will give eligible telehealth patients access to its self-pay prices for Zepbound and Foundayo without leaving the Hims & Hers service. source
• Eli Lilly signed an agreement allowing Hims & Hers users to access branded obesity drugs Zepbound and Foundayo directly through the telehealth platform, including integrated consultations and home delivery. source
• Eli Lilly partnered with Hims & Hers to offer Zepbound and Foundayo on its platform to eligible patients, who can complete consultations, receive prescriptions, and access the treatments through Hims & Hers digital services. source

Impact estimates